Skip to main content
SpringerLink
Log in

Should all patients with cystic fibrosis receive dornase alfa?

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wilson JW. Cystic fibrosis. New Ethicals 1997 Apr; 34: 43–4 & 46–7

    Google Scholar 

  2. Cramer GW, Bosso JA. The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother 1996 Jun; 30: 656–61

    PubMed  CAS  Google Scholar 

  3. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996 Jul 18; 335: 179–88

    Article  PubMed  CAS  Google Scholar 

  4. Hamer L, Parker HW. Treatment of cystic fibrosis in adults. Am Fam Physician 1996 Sep 15; 54: 1291–7

    PubMed  CAS  Google Scholar 

  5. Shah PL, Hodson ME. Dornase alfa: a practical guide to patient selection and drug use in cystic fibrosis. BioDrugs 1997 Dec; 8(6): 439–45

    Article  PubMed  CAS  Google Scholar 

  6. Goa KL, Lamb H. Dornase alfa: a review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis. Pharmacoeconomics 1997 Sep; 12(3): 409–22

    Article  PubMed  CAS  Google Scholar 

  7. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolised recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331: 637–42

    Article  PubMed  CAS  Google Scholar 

  8. Johnson C, Pulmozyme Severe Lung Disease Study Group. A multicentre, double-blind, placebo controlled study to evaluate the safety and efficacy of aerosolized rhDNase therapy in patients with cystic fibrosis who have advanced lung disease [abstract]. Pediatr Pulmonol 1994; Suppl. 10: 115

  9. Davis PB. Evolution of therapy for cystic fibrosis. N Engl J Med 1994; 331: 672–3

    Article  PubMed  CAS  Google Scholar 

  10. Smyth RL, Cheng K, Motley J. Systematic reviews in cystic fibrosis. J R Soc Med 1998 Jan; 91 (Suppl. 34): 19–24

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Should all patients with cystic fibrosis receive dornase alfa?. Drugs Ther. Perspect 13, 5–8 (1999). https://doi.org/10.2165/00042310-199913030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199913030-00003

Search

Navigation